CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.
|Videos|November 11, 2020
Surgeons Panel Discussion
Three esteemed surgeons discuss technology, weighing the pros and cons of existing and newly developed platforms.
Advertisement
Jon I. Einarsson, MD, PhD, MPH, Gaby Moawad, MD, and Robert K. Zurawin, MD.
Dr. Moawad is on the Speakers Bureau, Intuitive Surgical. Dr. Zurawin is principal medical advisor for Memic Innovative Surgery Ltd., the company that created the Hominis surgical system.
Advertisement
Related to this article
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Reactions to FDA's boxed warning removals for menopausal hormone therapy
2
Top headlines in women's health from October 2026
3
Top video interviews from The Menopause Society 2026 Annual Meeting
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5